BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohan CD, Hari S, Preetham HD, Rangappa S, Barash U, Ilan N, Nayak SC, Gupta VK, Basappa, Vlodavsky I, Rangappa KS. Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds. iScience 2019;15:360-90. [PMID: 31103854 DOI: 10.1016/j.isci.2019.04.034] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Bartolini B, Caravà E, Caon I, Parnigoni A, Moretto P, Passi A, Vigetti D, Viola M, Karousou E. Heparan Sulfate in the Tumor Microenvironment. Adv Exp Med Biol 2020;1245:147-61. [PMID: 32266657 DOI: 10.1007/978-3-030-40146-7_7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
2 Gerlza T, Trojacher C, Kitic N, Adage T, Kungl AJ. Development of Molecules Antagonizing Heparan Sulfate Proteoglycans. Semin Thromb Hemost 2021;47:316-32. [PMID: 33794555 DOI: 10.1055/s-0041-1725067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Masola V, Zaza G, Gambaro G, Franchi M, Onisto M. Role of heparanase in tumor progression: Molecular aspects and therapeutic options. Semin Cancer Biol 2020;62:86-98. [PMID: 31348993 DOI: 10.1016/j.semcancer.2019.07.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
4 Mohan CD, Liew YY, Jung YY, Rangappa S, Preetham HD, Chinnathambi A, Alahmadi TA, Alharbi SA, Lin ZX, Rangappa KS, Ahn KS. Brucein D modulates MAPK signaling cascade to exert multi-faceted anti-neoplastic actions against breast cancer cells. Biochimie 2021;182:140-51. [PMID: 33484785 DOI: 10.1016/j.biochi.2021.01.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Zahavi T, Salmon-Divon M, Salgado R, Elkin M, Hermano E, Rubinstein AM, Francis PA, Di Leo A, Viale G, de Azambuja E, Ameye L, Sotiriou C, Salmon A, Kravchenko-Balasha N, Sonnenblick A. Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. NPJ Breast Cancer 2021;7:67. [PMID: 34050190 DOI: 10.1038/s41523-021-00277-x] [Reference Citation Analysis]
6 Parate S, Kumar V, Danishuddin, Hong JC, Lee KW. Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics. Int J Mol Sci 2021;22:5311. [PMID: 34156395 DOI: 10.3390/ijms22105311] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Groult H, Carregal-Romero S, Castejón D, Azkargorta M, Miguel-Coello AB, Pulagam KR, Gómez-Vallejo V, Cousin R, Muñoz-Caffarel M, Lawrie CH, Llop J, Piot JM, Elortza F, Maugard T, Ruiz-Cabello J, Fruitier-Arnaudin I. Heparin length in the coating of extremely small iron oxide nanoparticles regulates in vivo theranostic applications. Nanoscale 2021;13:842-61. [PMID: 33351869 DOI: 10.1039/d0nr06378a] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ramchandani S, Mohan CD, Mistry JR, Su Q, Naz I, Rangappa KS, Ahn KS. The multifaceted antineoplastic role of pyrimethamine against different human malignancies. IUBMB Life 2021. [PMID: 34921584 DOI: 10.1002/iub.2590] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Faria-Ramos I, Poças J, Marques C, Santos-Antunes J, Macedo G, Reis CA, Magalhães A. Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management. Biomolecules 2021;11:136. [PMID: 33494442 DOI: 10.3390/biom11020136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
10 Zhu S, Li J, Loka RS, Song Z, Vlodavsky I, Zhang K, Nguyen HM. Modulating Heparanase Activity: Tuning Sulfation Pattern and Glycosidic Linkage of Oligosaccharides. J Med Chem 2020;63:4227-55. [PMID: 32216347 DOI: 10.1021/acs.jmedchem.0c00156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Liu J, Schleyer KA, Bryan TL, Xie C, Seabra G, Xu Y, Kafle A, Cui C, Wang Y, Yin K, Fetrow B, Henderson PKP, Fatland PZ, Liu J, Li C, Guo H, Cui L. Ultrasensitive small molecule fluorogenic probe for human heparanase. Chem Sci 2020;12:239-46. [PMID: 34163592 DOI: 10.1039/d0sc04872k] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Keerthy HK, Mohan S, Basappa, Bharathkumar H, Rangappa S, Svensson F, Bender A, Mohan CD, Rangappa KS, Bhatnagar R. Triazole-Pyridine Dicarbonitrile Targets Phosphodiesterase 4 to Induce Cytotoxicity in Lung Carcinoma Cells. Chem Biodivers 2019;16:e1900234. [PMID: 31287204 DOI: 10.1002/cbdv.201900234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
13 Teixeira FCOB, Götte M. Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation. Adv Exp Med Biol 2020;1221:97-135. [PMID: 32274708 DOI: 10.1007/978-3-030-34521-1_4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
14 Noda K, Philips BJ, Snyder ME, Phillippi JA, Sullivan M, Stolz DB, Ren X, Luketich JD, Sanchez PG. Heparanase inhibition preserves the endothelial glycocalyx in lung grafts and improves lung preservation and transplant outcomes. Sci Rep 2021;11:12265. [PMID: 34112915 DOI: 10.1038/s41598-021-91777-0] [Reference Citation Analysis]
15 Cousin R, Groult H, Manseur C, Ferru-Clément R, Gani M, Havret R, Toucheteau C, Prunier G, Colin B, Morel F, Piot JM, Lanneluc I, Baranger K, Maugard T, Fruitier-Arnaudin I. A Marine λ-Oligocarrageenan Inhibits Migratory and Invasive Ability of MDA-MB-231 Human Breast Cancer Cells through Actions on Heparanase Metabolism and MMP-14/MMP-2 Axis. Mar Drugs 2021;19:546. [PMID: 34677445 DOI: 10.3390/md19100546] [Reference Citation Analysis]
16 Dragostin OM, Tatia R, Samal SK, Oancea A, Zamfir AS, Dragostin I, Lisă EL, Apetrei C, Zamfir CL. Designing of Chitosan Derivatives Nanoparticles with Antiangiogenic Effect for Cancer Therapy. Nanomaterials (Basel) 2020;10:E698. [PMID: 32272625 DOI: 10.3390/nano10040698] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Arora L, Mohan CD, Yang MH, Rangappa S, Deivasigamani A, Kumar AP, Kunnumakkara AB, Garg M, Chinnathambi A, Alharbi SA, Alahmadi TA, Rangappa KS, Hui KM, Sethi G, Ahn KS. Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway. Cancers (Basel) 2021;13:5479. [PMID: 34771643 DOI: 10.3390/cancers13215479] [Reference Citation Analysis]
18 Lee JH, Rangappa S, Mohan CD, Sethi G, Lin ZX, Rangappa KS, Ahn KS; Basappa. Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma. Biomolecules 2019;9:E550. [PMID: 31575007 DOI: 10.3390/biom9100550] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
19 Berdiaki A, Neagu M, Giatagana EM, Kuskov A, Tsatsakis AM, Tzanakakis GN, Nikitovic D. Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy. Biomolecules 2021;11:395. [PMID: 33800172 DOI: 10.3390/biom11030395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Furini S, Falciani C. Expression and Role of Heparan Sulfated Proteoglycans in Pancreatic Cancer. Front Oncol 2021;11:695858. [PMID: 34249755 DOI: 10.3389/fonc.2021.695858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mohan CD, Rangappa S, Nayak SC, Jadimurthy R, Wang L, Sethi G, Garg M, Rangappa KS. Bacteria as a treasure house of secondary metabolites with anticancer potential. Semin Cancer Biol 2021:S1044-579X(21)00134-6. [PMID: 33979675 DOI: 10.1016/j.semcancer.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Fu K, Bai Z, Chen L, Ye W, Wang M, Hu J, Liu C, Zhou W. Antitumor activity and structure-activity relationship of heparanase inhibitors: Recent advances. Eur J Med Chem 2020;193:112221. [PMID: 32222663 DOI: 10.1016/j.ejmech.2020.112221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Tang WQ, Hei Y, Lin J. Heparanase-1 is downregulated in chemoradiotherapy orbital rhabdomyosarcoma and relates with tumor growth as well as angiogenesis. Int J Ophthalmol 2022;15:31-9. [PMID: 35047353 DOI: 10.18240/ijo.2022.01.05] [Reference Citation Analysis]
24 Chhabra M, Doherty GG, See NW, Gandhi NS, Ferro V. From Cancer to COVID-19: A Perspective on Targeting Heparan Sulfate-Protein Interactions. Chem Rec 2021. [PMID: 34145723 DOI: 10.1002/tcr.202100125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Mayfosh AJ, Nguyen TK, Hulett MD. The Heparanase Regulatory Network in Health and Disease. Int J Mol Sci 2021;22:11096. [PMID: 34681753 DOI: 10.3390/ijms222011096] [Reference Citation Analysis]
26 Eustes AS, Campbell RA, Middleton EA, Tolley ND, Manne BK, Montenont E, Rowley JW, Krauel K, Blair A, Guo L, Kosaka Y, Medeiros-de-Moraes IM, Lacerda M, Hottz ED, Neto HCF, Zimmerman GA, Weyrich AS, Petrey A, Rondina MT. Heparanase expression and activity are increased in platelets during clinical sepsis. J Thromb Haemost 2021;19:1319-30. [PMID: 33587773 DOI: 10.1111/jth.15266] [Reference Citation Analysis]
27 De Pasquale V, Pavone LM. Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment. Int J Mol Sci 2020;21:E6588. [PMID: 32916872 DOI: 10.3390/ijms21186588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
28 Barash U, Rangappa S, Mohan CD, Vishwanath D, Boyango I, Basappa B, Vlodavsky I, Rangappa KS. New Heparanase-Inhibiting Triazolo-Thiadiazoles Attenuate Primary Tumor Growth and Metastasis. Cancers (Basel) 2021;13:2959. [PMID: 34199150 DOI: 10.3390/cancers13122959] [Reference Citation Analysis]
29 Wagner MFMG, Theodoro TR, Filho CASM, Oyafuso LKM, Pinhal MAS. Extracellular matrix alterations in the skin of patients affected by psoriasis. BMC Mol Cell Biol 2021;22:55. [PMID: 34715781 DOI: 10.1186/s12860-021-00395-1] [Reference Citation Analysis]
30 Somu C, Mohan CD, Ambekar S, Dukanya, Rangappa S, Baburajeev CP, Sukhorukov A, Mishra S, Shanmugam MK, Chinnathambi A, Awad Alahmadi T, Alharbi SA, Basappa, Rangappa KS. Identification of a novel 1,2 oxazine that can induce apoptosis by targeting NF-κB in hepatocellular carcinoma cells. Biotechnol Rep (Amst) 2020;25:e00438. [PMID: 32140443 DOI: 10.1016/j.btre.2020.e00438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Whitefield C, Hong N, Mitchell JA, Jackson CJ. Computational design and experimental characterisation of a stable human heparanase variant. RSC Chem Biol . [DOI: 10.1039/d1cb00239b] [Reference Citation Analysis]
32 Ruszkowska-Ciastek B, Bielawski K, Zarychta E, Rhone P. Impact of Adjuvant Treatment on Heparanase Concentration in Invasive, Unilateral Breast Cancer Patients: Results of a Prospective Single-Centre Cohort Study. J Clin Med 2021;10:2184. [PMID: 34070058 DOI: 10.3390/jcm10102184] [Reference Citation Analysis]
33 Veraldi N, Zouggari N, de Agostini A. The Challenge of Modulating Heparan Sulfate Turnover by Multitarget Heparin Derivatives. Molecules 2020;25:E390. [PMID: 31963505 DOI: 10.3390/molecules25020390] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Kotian SY, Mohan CD, Merlo AA, Rangappa S, Nayak SC, Rai KL, Rangappa KS. Small molecule based five-membered heterocycles: A view of liquid crystalline properties beyond the biological applications. Journal of Molecular Liquids 2020;297:111686. [DOI: 10.1016/j.molliq.2019.111686] [Cited by in Crossref: 16] [Article Influence: 8.0] [Reference Citation Analysis]
35 Coombe DR, Gandhi NS. Heparanase: A Challenging Cancer Drug Target. Front Oncol 2019;9:1316. [PMID: 31850210 DOI: 10.3389/fonc.2019.01316] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
36 Pala D, Scalvini L, Elisi GM, Lodola A, Mor M, Spadoni G, Ferrara FF, Pavoni E, Roscilli G, Milazzo FM, Battistuzzi G, Rivara S, Giannini G. New classes of potent heparanase inhibitors from ligand-based virtual screening. J Enzyme Inhib Med Chem 2020;35:1685-96. [PMID: 32907434 DOI: 10.1080/14756366.2020.1811701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]